CN106834238B - A型流感病毒温度敏感性的关键磷酸化位点及其应用 - Google Patents
A型流感病毒温度敏感性的关键磷酸化位点及其应用 Download PDFInfo
- Publication number
- CN106834238B CN106834238B CN201710028543.8A CN201710028543A CN106834238B CN 106834238 B CN106834238 B CN 106834238B CN 201710028543 A CN201710028543 A CN 201710028543A CN 106834238 B CN106834238 B CN 106834238B
- Authority
- CN
- China
- Prior art keywords
- plasmid
- virus
- phh21
- sequence
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000712431 Influenza A virus Species 0.000 title claims abstract description 23
- 230000026731 phosphorylation Effects 0.000 title abstract description 18
- 238000006366 phosphorylation reaction Methods 0.000 title abstract description 18
- 230000035945 sensitivity Effects 0.000 title abstract description 6
- 241000700605 Viruses Species 0.000 claims abstract description 86
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 83
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 67
- 108020004705 Codon Proteins 0.000 claims abstract description 30
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 13
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 11
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims abstract description 7
- 239000013612 plasmid Substances 0.000 claims description 186
- 108020004414 DNA Proteins 0.000 claims description 45
- 102000053602 DNA Human genes 0.000 claims description 36
- 238000010367 cloning Methods 0.000 claims description 26
- 238000012258 culturing Methods 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract description 14
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract description 14
- 238000000034 method Methods 0.000 abstract description 9
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract description 8
- 125000000539 amino acid group Chemical group 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 238000004458 analytical method Methods 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 59
- 210000004027 cell Anatomy 0.000 description 38
- 102000004190 Enzymes Human genes 0.000 description 33
- 108090000790 Enzymes Proteins 0.000 description 33
- 229940088598 enzyme Drugs 0.000 description 33
- 239000000243 solution Substances 0.000 description 21
- 239000000047 product Substances 0.000 description 19
- 238000012408 PCR amplification Methods 0.000 description 18
- 238000010276 construction Methods 0.000 description 14
- 239000011324 bead Substances 0.000 description 13
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 12
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 108010019160 Pancreatin Proteins 0.000 description 7
- 239000012228 culture supernatant Substances 0.000 description 7
- 229940055695 pancreatin Drugs 0.000 description 7
- 210000001944 turbinate Anatomy 0.000 description 7
- 230000009385 viral infection Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000008300 Mutant Proteins Human genes 0.000 description 3
- 108010021466 Mutant Proteins Proteins 0.000 description 3
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 108010018691 arginyl-threonyl-arginine Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 108010056582 methionylglutamic acid Proteins 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 2
- AVEGDIAXTDVBJS-XUXIUFHCSA-N Leu-Ile-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AVEGDIAXTDVBJS-XUXIUFHCSA-N 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- JMGJDTNUMAZNLX-RWRJDSDZSA-N Thr-Glu-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JMGJDTNUMAZNLX-RWRJDSDZSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- 108010008355 arginyl-glutamine Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000000633 nuclear envelope Anatomy 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- TTXMOJWKNRJWQJ-FXQIFTODSA-N Ala-Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N TTXMOJWKNRJWQJ-FXQIFTODSA-N 0.000 description 1
- CXQODNIBUNQWAS-CIUDSAMLSA-N Ala-Gln-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N CXQODNIBUNQWAS-CIUDSAMLSA-N 0.000 description 1
- WKOBSJOZRJJVRZ-FXQIFTODSA-N Ala-Glu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WKOBSJOZRJJVRZ-FXQIFTODSA-N 0.000 description 1
- WUHJHHGYVVJMQE-BJDJZHNGSA-N Ala-Leu-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WUHJHHGYVVJMQE-BJDJZHNGSA-N 0.000 description 1
- CNQAFFMNJIQYGX-DRZSPHRISA-N Ala-Phe-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 CNQAFFMNJIQYGX-DRZSPHRISA-N 0.000 description 1
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 1
- OEVCHROQUIVQFZ-YTLHQDLWSA-N Ala-Thr-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O OEVCHROQUIVQFZ-YTLHQDLWSA-N 0.000 description 1
- KTXKIYXZQFWJKB-VZFHVOOUSA-N Ala-Thr-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O KTXKIYXZQFWJKB-VZFHVOOUSA-N 0.000 description 1
- BGGAIXWIZCIFSG-XDTLVQLUSA-N Ala-Tyr-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O BGGAIXWIZCIFSG-XDTLVQLUSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 1
- VWVPYNGMOCSSGK-GUBZILKMSA-N Arg-Arg-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O VWVPYNGMOCSSGK-GUBZILKMSA-N 0.000 description 1
- NKBQZKVMKJJDLX-SRVKXCTJSA-N Arg-Glu-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NKBQZKVMKJJDLX-SRVKXCTJSA-N 0.000 description 1
- RFXXUWGNVRJTNQ-QXEWZRGKSA-N Arg-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N RFXXUWGNVRJTNQ-QXEWZRGKSA-N 0.000 description 1
- NKNILFJYKKHBKE-WPRPVWTQSA-N Arg-Gly-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O NKNILFJYKKHBKE-WPRPVWTQSA-N 0.000 description 1
- PSOPJDUQUVFSLS-GUBZILKMSA-N Arg-Met-Cys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N PSOPJDUQUVFSLS-GUBZILKMSA-N 0.000 description 1
- ZEBDYGZVMMKZNB-SRVKXCTJSA-N Arg-Met-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCN=C(N)N)N ZEBDYGZVMMKZNB-SRVKXCTJSA-N 0.000 description 1
- XSPKAHFVDKRGRL-DCAQKATOSA-N Arg-Pro-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XSPKAHFVDKRGRL-DCAQKATOSA-N 0.000 description 1
- DNLQVHBBMPZUGJ-BQBZGAKWSA-N Arg-Ser-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O DNLQVHBBMPZUGJ-BQBZGAKWSA-N 0.000 description 1
- INOIAEUXVVNJKA-XGEHTFHBSA-N Arg-Thr-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O INOIAEUXVVNJKA-XGEHTFHBSA-N 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- LEFKSBYHUGUWLP-ACZMJKKPSA-N Asn-Ala-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LEFKSBYHUGUWLP-ACZMJKKPSA-N 0.000 description 1
- WVCJSDCHTUTONA-FXQIFTODSA-N Asn-Asp-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WVCJSDCHTUTONA-FXQIFTODSA-N 0.000 description 1
- PQAIOUVVZCOLJK-FXQIFTODSA-N Asn-Gln-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N PQAIOUVVZCOLJK-FXQIFTODSA-N 0.000 description 1
- IICZCLFBILYRCU-WHFBIAKZSA-N Asn-Gly-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IICZCLFBILYRCU-WHFBIAKZSA-N 0.000 description 1
- JLNFZLNDHONLND-GARJFASQSA-N Asn-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N JLNFZLNDHONLND-GARJFASQSA-N 0.000 description 1
- UOUHBHOBGDCQPQ-IHPCNDPISA-N Asn-Phe-Trp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)NC(=O)[C@H](CC(=O)N)N UOUHBHOBGDCQPQ-IHPCNDPISA-N 0.000 description 1
- PLTGTJAZQRGMPP-FXQIFTODSA-N Asn-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(N)=O PLTGTJAZQRGMPP-FXQIFTODSA-N 0.000 description 1
- GKKUBLFXKRDMFC-BQBZGAKWSA-N Asn-Pro-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O GKKUBLFXKRDMFC-BQBZGAKWSA-N 0.000 description 1
- JWQWPRCDYWNVNM-ACZMJKKPSA-N Asn-Ser-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N JWQWPRCDYWNVNM-ACZMJKKPSA-N 0.000 description 1
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 1
- KVMPVNGOKHTUHZ-GCJQMDKQSA-N Asp-Ala-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KVMPVNGOKHTUHZ-GCJQMDKQSA-N 0.000 description 1
- VGRHZPNRCLAHQA-IMJSIDKUSA-N Asp-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O VGRHZPNRCLAHQA-IMJSIDKUSA-N 0.000 description 1
- KHBLRHKVXICFMY-GUBZILKMSA-N Asp-Glu-Lys Chemical compound N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O KHBLRHKVXICFMY-GUBZILKMSA-N 0.000 description 1
- SCQIQCWLOMOEFP-DCAQKATOSA-N Asp-Leu-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O SCQIQCWLOMOEFP-DCAQKATOSA-N 0.000 description 1
- YTXCCDCOHIYQFC-GUBZILKMSA-N Asp-Met-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O YTXCCDCOHIYQFC-GUBZILKMSA-N 0.000 description 1
- QOJJMJKTMKNFEF-ZKWXMUAHSA-N Asp-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O QOJJMJKTMKNFEF-ZKWXMUAHSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- WAJDEKCJRKGRPG-CIUDSAMLSA-N Cys-His-Ser Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N WAJDEKCJRKGRPG-CIUDSAMLSA-N 0.000 description 1
- GGRDJANMZPGMNS-CIUDSAMLSA-N Cys-Ser-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O GGRDJANMZPGMNS-CIUDSAMLSA-N 0.000 description 1
- WVWRADGCZPIJJR-IHRRRGAJSA-N Cys-Val-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CS)N WVWRADGCZPIJJR-IHRRRGAJSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- WUAYFMZULZDSLB-ACZMJKKPSA-N Gln-Ala-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O WUAYFMZULZDSLB-ACZMJKKPSA-N 0.000 description 1
- DTMLKCYOQKZXKZ-HJGDQZAQSA-N Gln-Arg-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DTMLKCYOQKZXKZ-HJGDQZAQSA-N 0.000 description 1
- INFBPLSHYFALDE-ACZMJKKPSA-N Gln-Asn-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O INFBPLSHYFALDE-ACZMJKKPSA-N 0.000 description 1
- IOFDDSNZJDIGPB-GVXVVHGQSA-N Gln-Leu-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IOFDDSNZJDIGPB-GVXVVHGQSA-N 0.000 description 1
- XGKNQFOKIBKFTR-CIUDSAMLSA-N Gln-Met-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CCC(N)=O XGKNQFOKIBKFTR-CIUDSAMLSA-N 0.000 description 1
- PAOHIZNRJNIXQY-XQXXSGGOSA-N Gln-Thr-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O PAOHIZNRJNIXQY-XQXXSGGOSA-N 0.000 description 1
- OACPJRQRAHMQEQ-NHCYSSNCSA-N Gln-Val-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OACPJRQRAHMQEQ-NHCYSSNCSA-N 0.000 description 1
- CGYDXNKRIMJMLV-GUBZILKMSA-N Glu-Arg-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O CGYDXNKRIMJMLV-GUBZILKMSA-N 0.000 description 1
- LJLPOZGRPLORTF-CIUDSAMLSA-N Glu-Asn-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O LJLPOZGRPLORTF-CIUDSAMLSA-N 0.000 description 1
- RAUDKMVXNOWDLS-WDSKDSINSA-N Glu-Gly-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O RAUDKMVXNOWDLS-WDSKDSINSA-N 0.000 description 1
- VGOFRWOTSXVPAU-SDDRHHMPSA-N Glu-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)O)N)C(=O)O VGOFRWOTSXVPAU-SDDRHHMPSA-N 0.000 description 1
- FBEJIDRSQCGFJI-GUBZILKMSA-N Glu-Leu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O FBEJIDRSQCGFJI-GUBZILKMSA-N 0.000 description 1
- BPLNJYHNAJVLRT-ACZMJKKPSA-N Glu-Ser-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O BPLNJYHNAJVLRT-ACZMJKKPSA-N 0.000 description 1
- WIKMTDVSCUJIPJ-CIUDSAMLSA-N Glu-Ser-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N WIKMTDVSCUJIPJ-CIUDSAMLSA-N 0.000 description 1
- VNCNWQPIQYAMAK-ACZMJKKPSA-N Glu-Ser-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O VNCNWQPIQYAMAK-ACZMJKKPSA-N 0.000 description 1
- ZGXGVBYEJGVJMV-HJGDQZAQSA-N Glu-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O ZGXGVBYEJGVJMV-HJGDQZAQSA-N 0.000 description 1
- UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 1
- FMNHBTKMRFVGRO-FOHZUACHSA-N Gly-Asn-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CN FMNHBTKMRFVGRO-FOHZUACHSA-N 0.000 description 1
- XQHSBNVACKQWAV-WHFBIAKZSA-N Gly-Asp-Asn Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O XQHSBNVACKQWAV-WHFBIAKZSA-N 0.000 description 1
- BPQYBFAXRGMGGY-LAEOZQHASA-N Gly-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CN BPQYBFAXRGMGGY-LAEOZQHASA-N 0.000 description 1
- DHDOADIPGZTAHT-YUMQZZPRSA-N Gly-Glu-Arg Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DHDOADIPGZTAHT-YUMQZZPRSA-N 0.000 description 1
- HDNXXTBKOJKWNN-WDSKDSINSA-N Gly-Glu-Asn Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O HDNXXTBKOJKWNN-WDSKDSINSA-N 0.000 description 1
- BUEFQXUHTUZXHR-LURJTMIESA-N Gly-Gly-Pro zwitterion Chemical compound NCC(=O)NCC(=O)N1CCC[C@H]1C(O)=O BUEFQXUHTUZXHR-LURJTMIESA-N 0.000 description 1
- LHYJCVCQPWRMKZ-WEDXCCLWSA-N Gly-Leu-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LHYJCVCQPWRMKZ-WEDXCCLWSA-N 0.000 description 1
- MHXKHKWHPNETGG-QWRGUYRKSA-N Gly-Lys-Leu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O MHXKHKWHPNETGG-QWRGUYRKSA-N 0.000 description 1
- MHZXESQPPXOING-KBPBESRZSA-N Gly-Lys-Phe Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MHZXESQPPXOING-KBPBESRZSA-N 0.000 description 1
- IRJWAYCXIYUHQE-WHFBIAKZSA-N Gly-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CN IRJWAYCXIYUHQE-WHFBIAKZSA-N 0.000 description 1
- XHVONGZZVUUORG-WEDXCCLWSA-N Gly-Thr-Lys Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN XHVONGZZVUUORG-WEDXCCLWSA-N 0.000 description 1
- DNAZKGFYFRGZIH-QWRGUYRKSA-N Gly-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 DNAZKGFYFRGZIH-QWRGUYRKSA-N 0.000 description 1
- NGRPGJGKJMUGDM-XVKPBYJWSA-N Gly-Val-Gln Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O NGRPGJGKJMUGDM-XVKPBYJWSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- CKRJBQJIGOEKMC-SRVKXCTJSA-N His-Lys-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O CKRJBQJIGOEKMC-SRVKXCTJSA-N 0.000 description 1
- KQJBFMJFUXAYPK-AVGNSLFASA-N His-Met-Met Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N KQJBFMJFUXAYPK-AVGNSLFASA-N 0.000 description 1
- HDOYNXLPTRQLAD-JBDRJPRFSA-N Ile-Ala-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)O)N HDOYNXLPTRQLAD-JBDRJPRFSA-N 0.000 description 1
- TZCGZYWNIDZZMR-UHFFFAOYSA-N Ile-Arg-Ala Natural products CCC(C)C(N)C(=O)NC(C(=O)NC(C)C(O)=O)CCCN=C(N)N TZCGZYWNIDZZMR-UHFFFAOYSA-N 0.000 description 1
- HLYBGMZJVDHJEO-CYDGBPFRSA-N Ile-Arg-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N HLYBGMZJVDHJEO-CYDGBPFRSA-N 0.000 description 1
- WECYRWOMWSCWNX-XUXIUFHCSA-N Ile-Arg-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(O)=O WECYRWOMWSCWNX-XUXIUFHCSA-N 0.000 description 1
- DMHGKBGOUAJRHU-UHFFFAOYSA-N Ile-Arg-Pro Natural products CCC(C)C(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O DMHGKBGOUAJRHU-UHFFFAOYSA-N 0.000 description 1
- QTUSJASXLGLJSR-OSUNSFLBSA-N Ile-Arg-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N QTUSJASXLGLJSR-OSUNSFLBSA-N 0.000 description 1
- NKRJALPCDNXULF-BYULHYEWSA-N Ile-Asp-Gly Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O NKRJALPCDNXULF-BYULHYEWSA-N 0.000 description 1
- NPROWIBAWYMPAZ-GUDRVLHUSA-N Ile-Asp-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N NPROWIBAWYMPAZ-GUDRVLHUSA-N 0.000 description 1
- OVPYIUNCVSOVNF-ZPFDUUQYSA-N Ile-Gln-Pro Natural products CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O OVPYIUNCVSOVNF-ZPFDUUQYSA-N 0.000 description 1
- NHJKZMDIMMTVCK-QXEWZRGKSA-N Ile-Gly-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N NHJKZMDIMMTVCK-QXEWZRGKSA-N 0.000 description 1
- TVYWVSJGSHQWMT-AJNGGQMLSA-N Ile-Leu-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N TVYWVSJGSHQWMT-AJNGGQMLSA-N 0.000 description 1
- PWUMCBLVWPCKNO-MGHWNKPDSA-N Ile-Leu-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PWUMCBLVWPCKNO-MGHWNKPDSA-N 0.000 description 1
- XLXPYSDGMXTTNQ-DKIMLUQUSA-N Ile-Phe-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(O)=O XLXPYSDGMXTTNQ-DKIMLUQUSA-N 0.000 description 1
- XLXPYSDGMXTTNQ-UHFFFAOYSA-N Ile-Phe-Leu Natural products CCC(C)C(N)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 XLXPYSDGMXTTNQ-UHFFFAOYSA-N 0.000 description 1
- BLFXHAFTNYZEQE-VKOGCVSHSA-N Ile-Trp-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N BLFXHAFTNYZEQE-VKOGCVSHSA-N 0.000 description 1
- WJBOZUVRPOIQNN-KJYZGMDISA-N Ile-Trp-His Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)CC)C(O)=O)C1=CN=CN1 WJBOZUVRPOIQNN-KJYZGMDISA-N 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- KSZCCRIGNVSHFH-UWVGGRQHSA-N Leu-Arg-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O KSZCCRIGNVSHFH-UWVGGRQHSA-N 0.000 description 1
- UCOCBWDBHCUPQP-DCAQKATOSA-N Leu-Arg-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O UCOCBWDBHCUPQP-DCAQKATOSA-N 0.000 description 1
- AUBMZAMQCOYSIC-MNXVOIDGSA-N Leu-Ile-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O AUBMZAMQCOYSIC-MNXVOIDGSA-N 0.000 description 1
- JNDYEOUZBLOVOF-AVGNSLFASA-N Leu-Leu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JNDYEOUZBLOVOF-AVGNSLFASA-N 0.000 description 1
- WMIOEVKKYIMVKI-DCAQKATOSA-N Leu-Pro-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WMIOEVKKYIMVKI-DCAQKATOSA-N 0.000 description 1
- IRMLZWSRWSGTOP-CIUDSAMLSA-N Leu-Ser-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O IRMLZWSRWSGTOP-CIUDSAMLSA-N 0.000 description 1
- IZPVWNSAVUQBGP-CIUDSAMLSA-N Leu-Ser-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IZPVWNSAVUQBGP-CIUDSAMLSA-N 0.000 description 1
- FBNPMTNBFFAMMH-AVGNSLFASA-N Leu-Val-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-AVGNSLFASA-N 0.000 description 1
- FBNPMTNBFFAMMH-UHFFFAOYSA-N Leu-Val-Arg Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(=O)NC(C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-UHFFFAOYSA-N 0.000 description 1
- AAKRWBIIGKPOKQ-ONGXEEELSA-N Leu-Val-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AAKRWBIIGKPOKQ-ONGXEEELSA-N 0.000 description 1
- NQCJGQHHYZNUDK-DCAQKATOSA-N Lys-Arg-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CCCN=C(N)N NQCJGQHHYZNUDK-DCAQKATOSA-N 0.000 description 1
- YEIYAQQKADPIBJ-GARJFASQSA-N Lys-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)N)C(=O)O YEIYAQQKADPIBJ-GARJFASQSA-N 0.000 description 1
- PBIPLDMFHAICIP-DCAQKATOSA-N Lys-Glu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PBIPLDMFHAICIP-DCAQKATOSA-N 0.000 description 1
- CANPXOLVTMKURR-WEDXCCLWSA-N Lys-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN CANPXOLVTMKURR-WEDXCCLWSA-N 0.000 description 1
- PLDJDCJLRCYPJB-VOAKCMCISA-N Lys-Lys-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PLDJDCJLRCYPJB-VOAKCMCISA-N 0.000 description 1
- CTJUSALVKAWFFU-CIUDSAMLSA-N Lys-Ser-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N CTJUSALVKAWFFU-CIUDSAMLSA-N 0.000 description 1
- RYOLKFYZBHMYFW-WDSOQIARSA-N Lys-Trp-Arg Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 RYOLKFYZBHMYFW-WDSOQIARSA-N 0.000 description 1
- MIMXMVDLMDMOJD-BZSNNMDCSA-N Lys-Tyr-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O MIMXMVDLMDMOJD-BZSNNMDCSA-N 0.000 description 1
- YRAWWKUTNBILNT-FXQIFTODSA-N Met-Ala-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YRAWWKUTNBILNT-FXQIFTODSA-N 0.000 description 1
- HUKLXYYPZWPXCC-KZVJFYERSA-N Met-Ala-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HUKLXYYPZWPXCC-KZVJFYERSA-N 0.000 description 1
- UOENBSHXYCHSAU-YUMQZZPRSA-N Met-Gln-Gly Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O UOENBSHXYCHSAU-YUMQZZPRSA-N 0.000 description 1
- JPCHYAUKOUGOIB-HJGDQZAQSA-N Met-Glu-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPCHYAUKOUGOIB-HJGDQZAQSA-N 0.000 description 1
- RRIHXWPHQSXHAQ-XUXIUFHCSA-N Met-Ile-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(O)=O RRIHXWPHQSXHAQ-XUXIUFHCSA-N 0.000 description 1
- PCTFVQATEGYHJU-FXQIFTODSA-N Met-Ser-Asn Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O PCTFVQATEGYHJU-FXQIFTODSA-N 0.000 description 1
- CKAVKDJBSNTJDB-SRVKXCTJSA-N Met-Val-Met Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCSC CKAVKDJBSNTJDB-SRVKXCTJSA-N 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- 108010066427 N-valyltryptophan Proteins 0.000 description 1
- 108010047562 NGR peptide Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- XMPUYNHKEPFERE-IHRRRGAJSA-N Phe-Asp-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 XMPUYNHKEPFERE-IHRRRGAJSA-N 0.000 description 1
- DDYIRGBOZVKRFR-AVGNSLFASA-N Phe-Asp-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N DDYIRGBOZVKRFR-AVGNSLFASA-N 0.000 description 1
- LLGTYVHITPVGKR-RYUDHWBXSA-N Phe-Gln-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O LLGTYVHITPVGKR-RYUDHWBXSA-N 0.000 description 1
- MPFGIYLYWUCSJG-AVGNSLFASA-N Phe-Glu-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 MPFGIYLYWUCSJG-AVGNSLFASA-N 0.000 description 1
- FXPZZKBHNOMLGA-HJWJTTGWSA-N Phe-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N FXPZZKBHNOMLGA-HJWJTTGWSA-N 0.000 description 1
- BSKMOCNNLNDIMU-CDMKHQONSA-N Phe-Thr-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O BSKMOCNNLNDIMU-CDMKHQONSA-N 0.000 description 1
- MMPBPRXOFJNCCN-ZEWNOJEFSA-N Phe-Tyr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O MMPBPRXOFJNCCN-ZEWNOJEFSA-N 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- LNLNHXIQPGKRJQ-SRVKXCTJSA-N Pro-Arg-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1 LNLNHXIQPGKRJQ-SRVKXCTJSA-N 0.000 description 1
- XZGWNSIRZIUHHP-SRVKXCTJSA-N Pro-Arg-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1 XZGWNSIRZIUHHP-SRVKXCTJSA-N 0.000 description 1
- OBVCYFIHIIYIQF-CIUDSAMLSA-N Pro-Asn-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O OBVCYFIHIIYIQF-CIUDSAMLSA-N 0.000 description 1
- AUQGUYPHJSMAKI-CYDGBPFRSA-N Pro-Ile-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 AUQGUYPHJSMAKI-CYDGBPFRSA-N 0.000 description 1
- QKDIHFHGHBYTKB-IHRRRGAJSA-N Pro-Ser-Phe Chemical compound N([C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C(=O)[C@@H]1CCCN1 QKDIHFHGHBYTKB-IHRRRGAJSA-N 0.000 description 1
- CHYAYDLYYIJCKY-OSUNSFLBSA-N Pro-Thr-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CHYAYDLYYIJCKY-OSUNSFLBSA-N 0.000 description 1
- JDJMFMVVJHLWDP-UNQGMJICSA-N Pro-Thr-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JDJMFMVVJHLWDP-UNQGMJICSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 1
- FIDMVVBUOCMMJG-CIUDSAMLSA-N Ser-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO FIDMVVBUOCMMJG-CIUDSAMLSA-N 0.000 description 1
- CJINPXGSKSZQNE-KBIXCLLPSA-N Ser-Ile-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O CJINPXGSKSZQNE-KBIXCLLPSA-N 0.000 description 1
- RXUOAOOZIWABBW-XGEHTFHBSA-N Ser-Thr-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RXUOAOOZIWABBW-XGEHTFHBSA-N 0.000 description 1
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 1
- PMTWIUBUQRGCSB-FXQIFTODSA-N Ser-Val-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O PMTWIUBUQRGCSB-FXQIFTODSA-N 0.000 description 1
- LLSLRQOEAFCZLW-NRPADANISA-N Ser-Val-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LLSLRQOEAFCZLW-NRPADANISA-N 0.000 description 1
- MQBTXMPQNCGSSZ-OSUNSFLBSA-N Thr-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)O)CCCN=C(N)N MQBTXMPQNCGSSZ-OSUNSFLBSA-N 0.000 description 1
- SHOMROOOQBDGRL-JHEQGTHGSA-N Thr-Glu-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SHOMROOOQBDGRL-JHEQGTHGSA-N 0.000 description 1
- LHEZGZQRLDBSRR-WDCWCFNPSA-N Thr-Glu-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LHEZGZQRLDBSRR-WDCWCFNPSA-N 0.000 description 1
- UBDDORVPVLEECX-FJXKBIBVSA-N Thr-Gly-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O UBDDORVPVLEECX-FJXKBIBVSA-N 0.000 description 1
- XTCNBOBTROGWMW-RWRJDSDZSA-N Thr-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N XTCNBOBTROGWMW-RWRJDSDZSA-N 0.000 description 1
- VTVVYQOXJCZVEB-WDCWCFNPSA-N Thr-Leu-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O VTVVYQOXJCZVEB-WDCWCFNPSA-N 0.000 description 1
- GUHLYMZJVXUIPO-RCWTZXSCSA-N Thr-Met-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O GUHLYMZJVXUIPO-RCWTZXSCSA-N 0.000 description 1
- OFTGYORHQMSPAI-PJODQICGSA-N Trp-Met-Ala Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O OFTGYORHQMSPAI-PJODQICGSA-N 0.000 description 1
- WTXQBCCKXIKKHB-JYJNAYRXSA-N Tyr-Arg-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WTXQBCCKXIKKHB-JYJNAYRXSA-N 0.000 description 1
- WPVGRKLNHJJCEN-BZSNNMDCSA-N Tyr-Asp-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 WPVGRKLNHJJCEN-BZSNNMDCSA-N 0.000 description 1
- WAPFQMXRSDEGOE-IHRRRGAJSA-N Tyr-Glu-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O WAPFQMXRSDEGOE-IHRRRGAJSA-N 0.000 description 1
- HVHJYXDXRIWELT-RYUDHWBXSA-N Tyr-Glu-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O HVHJYXDXRIWELT-RYUDHWBXSA-N 0.000 description 1
- JXGUUJMPCRXMSO-HJOGWXRNSA-N Tyr-Phe-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 JXGUUJMPCRXMSO-HJOGWXRNSA-N 0.000 description 1
- ZYVAAYAOTVJBSS-GMVOTWDCSA-N Tyr-Trp-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(O)=O ZYVAAYAOTVJBSS-GMVOTWDCSA-N 0.000 description 1
- AZSHAZJLOZQYAY-FXQIFTODSA-N Val-Ala-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O AZSHAZJLOZQYAY-FXQIFTODSA-N 0.000 description 1
- QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 1
- SYOMXKPPFZRELL-ONGXEEELSA-N Val-Gly-Lys Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N SYOMXKPPFZRELL-ONGXEEELSA-N 0.000 description 1
- KZKMBGXCNLPYKD-YEPSODPASA-N Val-Gly-Thr Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O KZKMBGXCNLPYKD-YEPSODPASA-N 0.000 description 1
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 1
- YTNGABPUXFEOGU-SRVKXCTJSA-N Val-Pro-Arg Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O YTNGABPUXFEOGU-SRVKXCTJSA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- IECQJCJNPJVUSB-IHRRRGAJSA-N Val-Tyr-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(O)=O IECQJCJNPJVUSB-IHRRRGAJSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 108010010430 asparagine-proline-alanine Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000021040 cytoplasmic transport Effects 0.000 description 1
- WHHGLZMJPXIBIX-UHFFFAOYSA-N decabromodiphenyl ether Chemical compound BrC1=C(Br)C(Br)=C(Br)C(Br)=C1OC1=C(Br)C(Br)=C(Br)C(Br)=C1Br WHHGLZMJPXIBIX-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108700002148 exportin 1 Proteins 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 108010082286 glycyl-seryl-alanine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004492 nuclear pore Anatomy 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 108010084525 phenylalanyl-phenylalanyl-glycine Proteins 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 108010061514 sialic acid receptor Proteins 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种A型流感病毒温度敏感性的关键磷酸化位点及其应用。本发明首先保护一种重组病毒,命名为病毒WSN‑Y385F,是将A型流感病毒基因组中编码NP蛋白的第385位酪氨酸残基的密码子突变为苯丙氨酸残基的密码子得到的重组病毒。病毒WSN‑Y385F为温度敏感型病毒,在37℃可以正常复制并存活,在33℃不能正常复制并且不能存活。本发明还保护一种抑制A型流感病毒的NP蛋白发生磷酸化的方法,是将A型流感病毒的NP蛋白自N末端第385位氨基酸残基由酪氨酸突变为苯丙氨酸。本发明对于流感病毒侵染的机理分析,流感病毒的防治等具有重大价值。
Description
技术领域
本发明涉及一种A型流感病毒温度敏感性的关键磷酸化位点及其应用。
背景技术
A型流感病毒包含8个分节段的RNA片段,利用这些RNA片段,共能编码14种病毒蛋白。而病毒基因组的复制和转录需要由RNP复合物这一功能单元来完成。病毒感染宿主细胞面临着2层屏障,4次穿梭。
第一个屏障是病毒进入细胞需要穿过细胞质膜,这时病毒利用血凝素蛋白HA和细胞表面的唾液酸受体结合,进行发生内吞作用入侵到宿主细胞内部。
之后基质蛋白M1会释放vRNP复合物到细胞质中,而由于基因组复制和转录需要在细胞核内进行,此时的vRNP复合物面临的第二道屏障,即细胞核膜。vRNP会利用NP蛋白N端的非典型双向NLS同细胞核运输受体蛋白importin-α结合,从而得以穿过核孔复合物,进入到细胞核内部开始复制和转录。
转录产生的mRNA在细胞质得到翻译,新合成的病毒聚合酶组分又会分别利用自身的NLS进入到细胞核重新组装成RNP复合物。
待病毒基因组复制完毕后,RNP复合物会利用NP蛋白同M1蛋白和NEP蛋白形成一个大的复合物,再利用细胞质运输蛋白CRM1蛋白将之运输到细胞质中,完成再一次的穿梭屏障,然后组装成完整的病毒粒子。
NP蛋白在两次穿梭核膜的过程中,发挥着重要的作用。
发明内容
本发明的目的是提供一种A型流感病毒温度敏感性的关键磷酸化位点及其应用。
本发明首先保护一种重组病毒,命名为病毒WSN-Y385F,是将A型流感病毒基因组中编码NP蛋白的第385位酪氨酸残基的密码子突变为苯丙氨酸残基的密码子得到的重组病毒。病毒WSN-Y385F为温度敏感型病毒,在37℃可以正常复制并存活,在33℃不能正常复制并且不能存活。
所述A型流感病毒具体可为WSN病毒A/WSN/1933(H1N1)毒株。
所述NP蛋白如序列表的序列1所示。
本发明还保护一种蛋白质,命名为蛋白质NP-Y385F,是NP蛋白的第385位酪氨酸残基突变为苯丙氨酸残基得到的蛋白质。
所述NP蛋白如序列表的序列1所示。
编码蛋白质NP-Y385F的基因也属于本发明的保护范围。编码蛋白质NP-Y385F的基因命名为基因NP-Y385F。
基因NP-Y385F具体可为如下(a)或(b):
(a)编码区如序列表的序列10自5’末端第26-1522位核苷酸所示的DNA分子;
(b)序列表的序列10所示的DNA分子。
含有基因NP-Y385F的重组质粒也属于本发明的保护范围。
含有基因NP-Y385F的重组质粒具体可为重组质粒pHH21-NP-Y385F。重组质粒pHH21-NP-Y385F为:在载体pHH21的多克隆位点(例如BsmBI酶切位点)插入基因NP-Y385F得到的重组质粒。
含有基因NP-Y385F的重组质粒具体可为重组质粒pcDNA3.0-NP-Y385F。重组质粒pcDNA3.0-NP-Y385F为:在载体pcDNA3.0的多克隆位点(例如KpnI和XhoI酶切位点之间)插入基因NP-Y385F得到的重组质粒。
本发明还保护一种温度敏感型重组病毒,其制备方法包括如下步骤:
将质粒pHH21-PA、质粒pHH21-PB1、质粒pHH21-PB2、质粒pHH21-HA、质粒pHH21-NA、质粒pHH21-M、质粒pHH21-NS、质粒pcDNA3.0-PA、质粒pcDNA3.0-PB1、质粒pcDNA3.0-PB2、重组质粒pHH21-NP-Y385F和重组质粒pcDNA3.0-NP-Y385F共转染离体哺乳动物细胞后进行培养得到的重组病毒;
所述质粒pHH21-PA为在载体pHH21的多克隆位点(例如BsmBI酶切位点)插入序列表的序列3所示的双链DNA分子得到的质粒;所述质粒pHH21-PB1为在载体pHH21的多克隆位点(例如BsmBI酶切位点)插入序列表的序列4所示的双链DNA分子得到的质粒;所述质粒pHH21-PB2具体可为在载体pHH21的多克隆位点(例如BsmBI酶切位点)插入序列表的序列5所示的双链DNA分子得到的质粒;所述质粒pHH21-HA为在载体pHH21的多克隆位点(例如BsmBI酶切位点)插入序列表的序列6所示的双链DNA分子得到的质粒;所述质粒pHH21-NA为在载体pHH21的多克隆位点(例如BsmBI酶切位点)插入序列表的序列8所示的双链DNA分子得到的质粒;所述质粒pHH21-M为在载体pHH21的多克隆位点(例如BsmBI酶切位点)插入序列表的序列2所示的双链DNA分子得到的质粒;所述质粒pHH21-NS为在载体pHH21的多克隆位点(例如BsmBI酶切位点)插入序列表的序列9所示的双链DNA分子得到的质粒;所述质粒pcDNA3.0-PA为在载体pcDNA3.0的多克隆位点(例如KpnI和XhoI酶切位点之间)插入序列表的序列3所示的双链DNA分子得到的质粒;所述质粒pcDNA3.0-PB1为在载体pcDNA3.0的多克隆位点(例如KpnI和XhoI酶切位点之间)插入序列表的序列4所示的双链DNA分子得到的质粒;所述质粒pcDNA3.0-PB2为在载体pcDNA3.0的多克隆位点(例如KpnI和XhoI酶切位点之间)插入序列表的序列5所示的双链DNA分子得到的质粒;所述重组质粒pHH21-NP-Y385F为在载体pHH21的多克隆位点(例如BsmBI酶切位点)插入基因NP-Y385F得到的质粒;所述重组质粒pcDNA3.0-NP-Y385F为在载体pcDNA3.0的多克隆位点(例如KpnI和XhoI酶切位点之间)插入基因NP-Y385F得到的质粒。
所述哺乳动物细胞具体可为HEK 293T/17细胞。
所述培养的条件具体可为37℃培养6-78小时。
本发明还保护一种抑制A型流感病毒的NP蛋白发生磷酸化的方法,是将A型流感病毒的NP蛋白自N末端第385位氨基酸残基由酪氨酸突变为苯丙氨酸。
本发明还保护一种降低A型流感病毒的NP蛋白磷酸化水平的方法,是将A型流感病毒的NP蛋白自N末端第385位氨基酸残基由酪氨酸突变为苯丙氨酸。
本发明还保护一种抑制A型流感病毒的NP蛋白发生磷酸化的方法,是将A型流感病毒基因组中编码NP蛋白自N末端第385位氨基酸残基的密码子由酪氨酸密码子突变为苯丙氨酸密码子。
本发明还保护一种降低A型流感病毒的NP蛋白磷酸化水平的方法,是将A型流感病毒基因组中编码NP蛋白自N末端第385位氨基酸残基的密码子由酪氨酸密码子突变为苯丙氨酸密码子。
所述NP蛋白如序列表的序列1所示。
所述A型流感病毒具体可为WSN病毒A/WSN/1933(H1N1)毒株。
本发明还保护以上任一所述重组病毒在制备A型流感病毒疫苗中的应用。本发明还保护一种A型流感病毒疫苗,其活性成分为以上任一所述重组病毒。
本发明对于流感病毒侵染的机理分析,流感病毒的防治等具有重大价值。
附图说明
图1为实施例1的步骤一的结果。
图2为实施例1的步骤二的结果。
图3为实施例2的结果。
图4为实施例3的结果。
图5为实施例4的结果。
图6为实施例5的结果。
具体实施方式
以下的实施例便于更好地理解本发明,但并不限定本发明。下述实施例中的实验方法,如无特殊说明,均为常规方法。下述实施例中所用的试验材料,如无特殊说明,均为自常规生化试剂商店购买得到的。以下实施例中的定量试验,均设置三次重复实验,结果取平均值。
WSN病毒A/WSN/1933(H1N1)毒株:Neumann,G.et al.,Generation of influenzaA viruses entirely from cloned cDNAs.P Natl Acad Sci Usa 96(16),9345(1999)。WSN病毒即流感病毒。实施例中,采用病毒感染液调整病毒浓度从而实现不同剂量的感染。
载体pHH21:Neumann,G.et al.,Generation of influenza A viruses entirelyfrom cloned cDNAs.P Natl Acad Sci Usa 96(16),9345(1999)。
HEK 293T/17细胞(简称293T细胞衍生系,人胚肾细胞):ATCC,CRL-11268。载体pcDNA3.0:上海希匹吉生物技术有限公司,产品目录号CPC030。大肠杆菌DH5α:上海北诺生物科技有限公司。A549细胞(人肺腺癌细胞):上海拜力生物科技有限公司。BALB/c小鼠:北京维通利华实验动物技术有限公司。MDCK细胞:ATCC,CCL-34。
细胞裂解液(pH7.4):含150mM氯化钠、20mM HEPES、10%(体积比)甘油、1mM EDTA、1g/100mL NP40、蛋白酶抑制剂(cocktail),其余为水。
洗脱缓冲液:氯化钠的浓度为300mM,其它同细胞裂解液。
病毒感染液:含2μg/ml TPCK处理的胰酶(胰酶是以胰酶母液的方式加入的,胰酶母液为用PBS缓冲液配制的胰酶浓度为0.25g/100mL的溶液)、100U/ml青霉素和100U/ml链霉素的无血清DMEM培养基。
碱性磷酸酶:Takara,货号D2250。蛋白酶抑制剂(cocktail)购自Roche公司。SDM酶:北京赛百盛基因技术有限公司,货号:SDM-15。phos-tag SDS-PAGE中所用的凝胶为Phos-tag Acrylamide,购自Wako(日本)。抗磷酸化酪氨酸抗体(鼠单克隆抗体,sc-508)购自Santa Cruz。具有已知分子量的预先染色的蛋白标准品购自Thermo。氯化钠、N-(2-羟乙基)哌嗪-N’-2-乙烷磺酸(简称HEPES)、甘油、乙二胺四乙酸(简称EDTA)、Nonidet P-40(简称NP40)和TPCK处理的胰酶均购自Sigma。牛血清白蛋白(BSA)购自江晨生物。青霉素、链霉素购自碧云天公司。十二烷基硫酸钠(简称SDS)、低熔点琼脂糖购自Amersco公司。
抗NP蛋白的单抗(即抗A型流感病毒NP蛋白的鼠源单克隆抗体):M-R Yu#,X-LLiu#,Sh Cao,Zh-D Zhao,K Zhang,Q Xie,C-W Chen,Sh-Y Gao,Y-H Bi,L Sun,X Ye,George F.Gao,W-J Liu*.2012.Identification and Characterization of three novelnuclear export signals in influenza A virus nucleoprotein.Journal ofVirology,86(9):4970-80。
将质粒pHH21-PA、质粒pHH21-PB1、质粒pHH21-PB2、质粒pHH21-HA、质粒pHH21-NP、质粒pHH21-NA、质粒pHH21-M、质粒pHH21-NS、质粒pcDNA3.0-PA、质粒pcDNA3.0-PB1、质粒pcDNA3.0-PB2和质粒pcDNA3.0-NP共转染HEK 293T/17细胞,培养后得到WSN病毒A/WSN/1933(H1N1)毒株。WSN病毒A/WSN/1933(H1N1)毒株又称WSN病毒野生型。
实施例1、磷酸化NP蛋白的获得以及磷酸化位点的鉴定
一、磷酸化NP蛋白的获得
1、将A/WSN/1933(H1N1)毒株以MOI=0.1的剂量感染HEK 293T/17细胞,37℃培养12-16小时后收获细胞。
2、将步骤1收获的细胞用细胞裂解液4℃处理30分钟,12000rpm离心15min,收集上清液。
3、在步骤2得到的上清液中加入抗NP蛋白的单抗,4℃孵育1小时,然后加入protein G beads 4℃孵育3小时,吸弃上清,将珠子(beads)用洗脱缓冲液在4℃下洗3次(每次10分钟),与珠子(beads)结合的即为NP蛋白。
4、将步骤3获得的结合有NP蛋白的珠子用碱性磷酸酶37℃处理2小时(碱性磷酸酶的作用为:使磷酸化蛋白去磷酸化)。
5、将碱性磷酸酶处理前的NP蛋白(步骤3得到的)和碱性磷酸酶处理后的NP蛋白(步骤4得到的)分别进行磷酸化蛋白电泳(phos-tag SDS-PAGE)并银染显色。
结果见图1。图1中,泳道1为碱性磷酸酶处理后的NP蛋白,泳道2为碱性磷酸酶处理前的NP蛋白。将碱性磷酸酶处理后的NP蛋白作为标准NP蛋白,碱性磷酸酶处理前的NP蛋白在胶上出现比标准NP蛋白迁移速率慢且对碱性磷酸酶敏感的条带,即为磷酸化NP条带。结果表明,步骤3获得的NP蛋白为磷酸化蛋白,碱性磷酸酶可以使其发生去磷酸化反应。
二、质谱鉴定磷酸化位点
将磷酸化的NP条带从胶上切下,送样至中国科学院动物研究所大型仪器平台进行样品处理及质谱鉴定(Nano-LC MS/MS,LCQ DECA XPPLUS Thermo)。
结果见图2。B2与b3的核质比差值显示Y385被磷酸化修饰。鉴定结果显示,该条带为A型流感病毒的NP蛋白,且在385位酪氨酸残基处具有磷酸化修饰。
实施例2、突变蛋白的制备和磷酸化鉴定
一、构建重组质粒
1、构建质粒pHH21-PA
在载体pHH21的BsmBI酶切位点插入序列表的序列3所示的双链DNA分子,得到质粒pHH21-PA。
2、构建质粒pHH21-PB1
在载体pHH21的BsmBI酶切位点插入序列表的序列4所示的双链DNA分子,得到质粒pHH21-PB1。
3、构建质粒pHH21-PB2
在载体pHH21的BsmBI酶切位点插入序列表的序列5所示的双链DNA分子,得到质粒pHH21-PB2。
4、构建质粒pHH21-HA
在载体pHH21的BsmBI酶切位点插入序列表的序列6所示的双链DNA分子,得到质粒pHH21-HA。
5、构建质粒pHH21-NP
在载体pHH21的BsmBI酶切位点插入序列表的序列7所示的双链DNA分子,得到质粒pHH21-NP。
6、构建质粒pHH21-NA
在载体pHH21的BsmBI酶切位点插入序列表的序列8所示的双链DNA分子,得到质粒pHH21-NA。
7、构建质粒pHH21-M
在载体pHH21的BsmBI酶切位点插入序列表的序列2所示的双链DNA分子,得到质粒pHH21-M。
8、构建质粒pHH21-NS
在载体pHH21的BsmBI酶切位点插入序列表的序列9所示的双链DNA分子,得到质粒pHH21-NS。
9、构建质粒pcDNA3.0-PA
在载体pcDNA3.0的KpnI和XhoI酶切位点之间插入序列表的序列3所示的双链DNA分子,得到质粒pcDNA3.0-PA。
10、构建质粒pcDNA3.0-PB1
在载体pcDNA3.0的KpnI和XhoI酶切位点之间插入序列表的序列4所示的双链DNA分子,得到质粒pcDNA3.0-PB1。
11、构建质粒pcDNA3.0-PB2
在载体pcDNA3.0的KpnI和XhoI酶切位点之间插入序列表的序列5所示的双链DNA分子,得到质粒pcDNA3.0-PB2。
12、构建质粒pcDNA3.0-NP
在载体pcDNA3.0的KpnI和XhoI酶切位点之间插入序列表的序列7所示的双链DNA分子,得到质粒pcDNA3.0-NP。
13、构建重组质粒
NP-Y385A-F:5’-ctgagaagcagaGCGtgggccataaggaccagaagtggag-3’;
NP-Y385A-R:5’-ccttatggcccaCGCtctgcttctcagttcaagggtacttg-3’。
NP-Y385F-F:5’-ctgagaagcagaTTCtgggccataaggaccagaagtggag-3’;
NP-Y385F-R:5’-ccttatggcccaGAAtctgcttctcagttcaagggtacttg-3’。
NP-Y385E-F:5’-ctgagaagcagaGAGtgggccataaggaccagaagtggag-3’;
NP-Y385E-R:5’-ccttatggcccaCTCtctgcttctcagttcaagggtacttg-3’。
使用Newpep点突变试剂盒(Cat.No.80111-01,北京诺派生物科技有限公司)按试剂盒说明书构建各种重组质粒。
(1)以质粒pHH21-NP为模板,用NP-Y385A-F和NP-Y385A-R组成的引物对进行PCR扩增,得到PCR扩增产物(突变质粒)。
(2)用SDM酶在37℃酶切步骤(1)的PCR扩增产物2小时(消化模板质粒)。
(3)将步骤(2)的产物转化大肠杆菌DH5α的感受态细胞,得到重组菌Y385A-Ⅰ(即含有重组质粒pHH21-NP-Y385A的大肠杆菌)。根据测序结果,对重组质粒pHH21-NP-Y385A进行结构描述如下:将质粒pHH21-NP中的编码NP蛋白自N末端第385位酪氨酸的密码子“tac”突变为了丙氨酸的密码子“GCG”。
(4)以pcDNA3.0-NP为模板,用NP-Y385A-F和NP-Y385A-R组成的引物对进行PCR扩增,得到PCR扩增产物(突变质粒)。
(5)用SDM酶在37℃酶切步骤(4)的PCR扩增产物2小时(消化模板质粒)。
(6)将步骤(5)的产物转化大肠杆菌DH5α的感受态细胞,得到重组菌Y385A-Ⅱ(即含有重组质粒pcDNA3.0-NP-Y385A的大肠杆菌)。根据测序结果,对重组质粒pcDNA3.0-NP-Y385A进行结构描述如下:将质粒pcDNA3.0-NP中的编码NP蛋白自N末端第385位酪氨酸的密码子“tac”突变为了丙氨酸的密码子“GCG”。
(7)以质粒pHH21-NP为模板,用NP-Y385F-F和NP-Y385F-R组成的引物对进行PCR扩增,得到PCR扩增产物(突变质粒)。
(8)用SDM酶在37℃酶切步骤(7)的PCR扩增产物2小时(消化模板质粒)。
(9)将步骤(8)的产物转化大肠杆菌DH5α的感受态细胞,得到重组菌Y385F-Ⅰ(即含有重组质粒pHH21-NP-Y385F的大肠杆菌)。根据测序结果,对重组质粒pHH21-NP-Y385F进行结构描述如下:将质粒pHH21-NP中的编码NP蛋白自N末端第385位酪氨酸的密码子“tac”突变为了苯丙氨酸的密码子“TTC”;也就是说,在载体pHH21的BsmBI酶切位点插入序列表的序列10所示的双链DNA分子。
(10)以质粒pcDNA3.0-NP为模板,用NP-Y385F-F和NP-Y385F-R组成的引物对进行PCR扩增,得到PCR扩增产物(突变质粒)。
(11)用SDM酶在37℃酶切步骤(10)的PCR扩增产物2小时(消化模板质粒)。
(12)将步骤(11)的产物转化大肠杆菌DH5α的感受态细胞,得到重组菌Y385F-Ⅱ(即含有重组质粒pcDNA3.0-NP-Y385F的大肠杆菌)。根据测序结果,对重组质粒pcDNA3.0-NP-Y385F进行结构描述如下:将质粒pcDNA3.0-NP中的编码NP蛋白自N末端第385位酪氨酸的密码子“tac”突变为了苯丙氨酸的密码子“TTC”;也就是说,在载体pcDNA3.0的KpnI和XhoI酶切位点之间插入了序列表的序列10所示的双链DNA分子。
(13)以质粒pHH21-NP为模板,用NP-Y385E-F和NP-Y385E-R组成的引物对进行PCR扩增,得到PCR扩增产物(突变质粒)。
(14)用SDM酶在37℃酶切步骤(13)的PCR扩增产物2小时(消化模板质粒)。
(15)将步骤(14)的产物转化大肠杆菌DH5α的感受态细胞,得到重组菌Y385E-Ⅰ(即含有重组质粒pHH21-NP-Y385E的大肠杆菌)。根据测序结果,对重组质粒pHH21-NP-Y385E进行结构描述如下:将质粒pHH21-NP中的编码NP蛋白自N末端第385位酪氨酸的密码子“tac”突变为了谷氨酸的密码子“GAG”。
(16)以质粒pcDNA3.0-NP为模板,用NP-Y385E-F和NP-Y385E-R组成的引物对进行PCR扩增,得到PCR扩增产物(突变质粒)。
(17)用SDM酶在37℃酶切步骤(16)的PCR扩增产物2小时(消化模板质粒)。
(18)将步骤(17)的产物转化大肠杆菌DH5α的感受态细胞,得到重组菌Y385E-Ⅱ(即含有重组质粒pcDNA3.0-NP-Y385E的大肠杆菌)。根据测序结果,对重组质粒pcDNA3.0-NP-Y385E进行结构描述如下:将质粒pcDNA3.0-NP中的编码NP蛋白自N末端第385位酪氨酸的密码子“tac”突变为了谷氨酸的密码子“GAG”。
二、突变蛋白的制备
1、Y385F突变蛋白的制备
(1)将质粒pHH21-PA、质粒pHH21-PB1、质粒pHH21-PB2、质粒pHH21-HA、重组质粒pHH21-NP-Y385F、质粒pHH21-NA、质粒pHH21-M、质粒pHH21-NS、质粒pcDNA3.0-PA、质粒pcDNA3.0-PB1、质粒pcDNA3.0-PB2和重组质粒pcDNA3.0-NP-Y385F以等质量的配比通过脂质体Lipofectamine2000(Invitrogen)共转染HEK 293T/17细胞,37℃培养6小时。
(2)更换步骤(1)的细胞的培养基为病毒感染液,37℃培养72小时后收获细胞。
(3)将步骤(2)收获的细胞用细胞裂解液4℃处理30分钟,12000rpm离心15min,收集上清液。
(4)在步骤(3)得到的上清液中加入抗NP蛋白的单抗,4℃孵育1小时,然后加入protein G beads 4℃孵育3小时,吸弃上清,将珠子(beads)用洗脱缓冲液在4℃下洗3次(每次10分钟),与珠子(beads)结合的即为Y385F突变蛋白。
2、NP蛋白的制备
用质粒pHH21-NP代替重组质粒pHH21-NP-Y385F并且用质粒pcDNA3.0-NP代替重组质粒pcDNA3.0-NP-Y385F,其它同步骤1,与珠子(beads)结合的即为NP蛋白。
3、Western Blot检测
将步骤1和步骤2得到的蛋白分别进行western blot,采用的一抗为抗磷酸化酪氨酸抗体,采用的二抗为HRP标记的羊抗鼠IgG。
结果见图3。结果表明,与NP蛋白相比Y385F突变蛋白的磷酸化水平显著下降,即NP蛋白第385位的酪氨酸残基为主要的磷酸化位点。
实施例3、病毒拯救
1、将HEK 293T/17细胞接种于60mm平皿,每皿1×106个细胞,培养12小时。
2、完成步骤1后,对HEK 293T/17细胞进行分组处理如下:
第一组:将质粒pHH21-PA、质粒pHH21-PB1、质粒pHH21-PB2、质粒pHH21-HA、重组质粒pHH21-NP-Y385A、质粒pHH21-NA、质粒pHH21-M、质粒pHH21-NS、质粒pcDNA3.0-PA、质粒pcDNA3.0-PB1、质粒pcDNA3.0-PB2和重组质粒pcDNA3.0-NP-Y385A各0.5μg通过脂质体Lipofectamine2000(Invitrogen)共转染HEK 293T/17细胞,37℃培养6小时后更换培养基为病毒感染液,继续培养72小时后收获细胞。
第二组:与第一组的差异仅在于用重组质粒pHH21-NP-Y385F代替重组质粒pHH21-NP-Y385A并且用重组质粒pcDNA3.0-NP-Y385F代替重组质粒pcDNA3.0-NP-Y385A。
第三组:与第一组的差异仅在于用重组质粒pHH21-NP-Y385E代替重组质粒pHH21-NP-Y385A并且用重组质粒pcDNA3.0-NP-Y385E代替重组质粒pcDNA3.0-NP-Y385A。
第四组:与第一组的差异仅在于用质粒pHH21-NP代替重组质粒pHH21-NP-Y385A并且用质粒pcDNA3.0-NP代替重组质粒pcDNA3.0-NP-Y385A。
3、完成步骤2后,各组分别收获培养上清。
第四组得到的培养上清中含WSN病毒野生型,因此该将培养上清命名为WSN-WT病毒液。
第一组得到的培养上清中含有WSN病毒突变型(突变病毒基因组中编码NP蛋白自N末端第385位酪氨酸的密码子突变为了丙氨酸的密码子,将该突变病毒命名为WSN-Y385A病毒),因此该将培养上清命名为WSN-Y385A病毒液。
第二组得到的培养上清中含有WSN病毒突变型(突变病毒基因组中编码NP蛋白自N末端第385位酪氨酸的密码子突变为了苯丙氨酸的密码子,将该突变病毒命名为WSN-Y385F病毒),因此该将培养上清命名为WSN-Y385F病毒液。
第三组得到的培养上清中含有WSN病毒突变型(突变病毒基因组中编码NP蛋白自N末端第385位酪氨酸的密码子突变为了谷氨酸的密码子,将该突变病毒命名为WSN-Y385E病毒),因此该将培养上清命名为WSN-Y385E病毒液。
4、取步骤3得到的各个病毒液,通过噬斑鉴定检测病毒滴度。
噬斑鉴定的方法:(1)将MDCK细胞接种于12孔板中,每孔约1×105个细胞,37℃、5%CO2培养箱中培养过夜;(2)用PBS缓冲液洗去细胞表面的培养基,将待测的病毒液用病毒感染液梯度稀释后分别加入各孔中,每个稀释度设置三个重复孔,37℃孵育1小时;(3)吸弃上清并用PBS缓冲液清洗细胞,每孔加入1毫升混合溶液(混合溶液的制备方法:将1体积份融化后降温至37℃左右的3%低熔点琼脂糖与1体积份预热到37℃的无酚红DMEM培养基等体积混合,且混合物中加入TPCK处理的胰酶、青霉素和链霉素,使得胰酶浓度为2μg/ml,青霉素和链霉素的浓度均为100U/ml);(4)将12孔板4℃放置15分钟以上,待琼脂凝固后,将孔板翻转过来倒置在37℃培养箱中培养,在显微镜下观察细胞病变情况,培养3天(实际应用中,2-4天均可)后,将12孔板从培养箱中取出,计数空斑数。
WSN-WT病毒液的滴度为6.512log10PFU/ml。WSN-Y385F病毒液的滴度为7.179log10PFU/ml。WSN-Y385A病毒液的滴度为0,即不能使MDCK产生噬斑。WSN-Y385E病毒液的滴度为0,即不能使MDCK产生噬斑。
5、完成步骤2后,各组分别收获细胞,将细胞破碎后进行western blot(检测各主要病毒蛋白的表达)。
Western Blot中:用于检测NP蛋白的一抗购自Thermo Scientific公司,产品目录号:PA5-32242;用于检测M1蛋白的一抗为抗M1蛋白的单抗。
结果见图4。各组重组系统中流感病毒的两种重要蛋白(NP蛋白、M1蛋白)均能够正常表达。
实施例4、细胞水平下不同温度下病毒生长曲线的差异
1、将A549细胞接种于10cm平皿,每皿1×108个细胞,培养12小时。
2、完成步骤1后,对A549细胞进行分组处理如下:
第一组:将实施例3制备的WSN-WT病毒液(病毒剂量为106PFU)接种A549细胞,接种后1小时换液为病毒感染液;37℃培养,分别于接种12、24、36、48、60、72小时后收取上清液,通过噬斑鉴定检测病毒滴度。
第二组:将实施例3制备的WSN-Y385F病毒液(病毒剂量为106PFU)接种A549细胞,接种后1小时换液为病毒感染液;37℃培养,分别于接种12、24、36、48、60、72小时后收取上清液,通过噬斑鉴定检测病毒滴度。
第三组:与第一组的差异仅在于培养温度由37℃改为33℃。
第四组:与第二组的差异仅在于培养温度由37℃改为33℃。
噬斑鉴定的方法同实施例3。
每组设置10个重复处理,结果取平均值。
结果见图5。图5中,A为第三组和第四组的结果,B为第一组和第二组的结果。
33℃培养过程中,WSN-WT病毒均能正常复制,病毒滴度保持相对稳定、缓慢上升的趋势。33℃培养24小时后,WSN-Y385F病毒滴度为0,即WSN-Y385F病毒在33℃不能复制。37℃培养过程中,WSN-WT病毒和WSN-Y385F病毒均能正常复制,病毒滴度均保持相对稳定、缓慢上升的趋势。结果表明,WSN-Y385F病毒为温度敏感性病毒。
实施例5、动物水平下不同温度下病毒生长曲线的差异
36只体重约17g的6-8周龄BALB/c小鼠经过乙醚麻醉后随机分为三组,每组12只,分别进行如下处理:
第一组:利用鼻吸法吸入50μl实施例3制备的WSN-WT病毒液(病毒滴度为104PFU/ml);
第二组:利用鼻吸法吸入50μl实施例3制备的WSN-Y385F病毒液(病毒滴度为104PFU/ml);
第三组:利用鼻吸法吸入50μl灭菌后的PBS缓冲液。
完成上述处理后开始计时,分别于第1天、第3天、第5天、第7天时解剖小鼠(每个时间点每组取3只小鼠),获得小鼠肺脏和鼻甲骨(鼻甲骨和肺的温度不同,鼻甲骨温度较低、约为33℃,肺部温度较高、约为37℃)。
取0.1g鲜重的肺脏或鼻甲骨,加入1ml冰浴的pH7.2的PBS缓冲液,采用QIAGENTissueLyser II进行组织匀浆(匀浆参数:30循环/s,共计4min),然后5000g离心10min,收集上清液。
通过噬斑鉴定检测上清液中的病毒滴度(噬斑鉴定方法同实施例3)。
结果见图6。图6中,A为肺脏结果,B为鼻甲骨的结果。
鼻甲骨中,WSN-WT病毒均能正常复制,病毒滴度保持相对稳定、缓慢下降的趋势。鼻甲骨中,WSN-Y385F病毒滴度为0,即WSN-Y385F病毒在33℃不能复制。肺脏中,WSN-WT病毒和WSN-Y385F病毒均能正常复制,病毒滴度均保持相对稳定、缓慢下降的趋势。结果表明,WSN-Y385F病毒为温度敏感性病毒。
序列表
<110> A型流感病毒温度敏感性的关键磷酸化位点及其应用
<120> 中国科学院微生物研究所
<130> GNCYX170081
<160> 10
<210> 1
<211> 498
<212> PRT
<213> 人工序列
<400> 1
Met Ala Thr Lys Gly Thr Lys Arg Ser Tyr Glu Gln Met Glu Thr Asp
1 5 10 15
Gly Glu Arg Gln Asn Ala Thr Glu Ile Arg Ala Ser Val Gly Lys Met
20 25 30
Ile Asp Gly Ile Gly Arg Phe Tyr Ile Gln Met Cys Thr Glu Leu Lys
35 40 45
Leu Ser Asp Tyr Glu Gly Arg Leu Ile Gln Asn Ser Leu Thr Ile Glu
50 55 60
Arg Met Val Leu Ser Ala Phe Asp Glu Arg Arg Asn Lys Tyr Leu Glu
65 70 75 80
Glu His Pro Ser Ala Gly Lys Asp Pro Lys Lys Thr Gly Gly Pro Ile
85 90 95
Tyr Arg Arg Val Asp Gly Lys Trp Arg Arg Glu Leu Ile Leu Tyr Asp
100 105 110
Lys Glu Glu Ile Arg Arg Ile Trp Arg Gln Ala Asn Asn Gly Asp Asp
115 120 125
Ala Thr Ala Gly Leu Thr His Met Met Ile Trp His Ser Asn Leu Asn
130 135 140
Asp Ala Thr Tyr Gln Arg Thr Arg Ala Leu Val Arg Thr Gly Met Asp
145 150 155 160
Pro Arg Met Cys Ser Leu Met Gln Gly Ser Thr Leu Pro Arg Arg Ser
165 170 175
Gly Ala Ala Gly Ala Ala Val Lys Gly Val Gly Thr Met Val Met Glu
180 185 190
Leu Ile Arg Met Ile Lys Arg Gly Ile Asn Asp Arg Asn Phe Trp Arg
195 200 205
Gly Glu Asn Gly Arg Arg Thr Arg Ile Ala Tyr Glu Arg Met Cys Asn
210 215 220
Ile Leu Lys Gly Lys Phe Gln Thr Ala Ala Gln Arg Thr Met Val Asp
225 230 235 240
Gln Val Arg Glu Ser Arg Asn Pro Gly Asn Ala Glu Phe Glu Asp Leu
245 250 255
Ile Phe Leu Ala Arg Ser Ala Leu Ile Leu Arg Gly Ser Val Ala His
260 265 270
Lys Ser Cys Leu Pro Ala Cys Val Tyr Gly Ser Ala Val Ala Ser Gly
275 280 285
Tyr Asp Phe Glu Arg Glu Gly Tyr Ser Leu Val Gly Ile Asp Pro Phe
290 295 300
Arg Leu Leu Gln Asn Ser Gln Val Tyr Ser Leu Ile Arg Pro Asn Glu
305 310 315 320
Asn Pro Ala His Lys Ser Gln Leu Val Trp Met Ala Cys His Ser Ala
325 330 335
Ala Phe Glu Asp Leu Arg Val Ser Ser Phe Ile Arg Gly Thr Lys Val
340 345 350
Val Pro Arg Gly Lys Leu Ser Thr Arg Gly Val Gln Ile Ala Ser Asn
355 360 365
Glu Asn Met Glu Thr Met Glu Ser Ser Thr Leu Glu Leu Arg Ser Arg
370 375 380
Tyr Trp Ala Ile Arg Thr Arg Ser Gly Gly Asn Thr Asn Gln Gln Arg
385 390 395 400
Ala Ser Ser Gly Gln Ile Ser Ile Gln Pro Thr Phe Ser Val Gln Arg
405 410 415
Asn Leu Pro Phe Asp Arg Pro Thr Ile Met Ala Ala Phe Thr Gly Asn
420 425 430
Thr Glu Gly Arg Thr Ser Asp Met Arg Thr Glu Ile Ile Arg Leu Met
435 440 445
Glu Ser Ala Arg Pro Glu Asp Val Ser Phe Gln Gly Arg Gly Val Phe
450 455 460
Glu Leu Ser Asp Glu Lys Ala Thr Ser Pro Ile Val Pro Ser Phe Asp
465 470 475 480
Met Ser Asn Glu Gly Ser Tyr Phe Phe Gly Asp Asn Ala Glu Glu Tyr
485 490 495
Asp Asn
<210> 2
<211> 984
<212> DNA
<213> 人工序列
<400> 2
atgagtcttc taaccgaggt cgaaacgtac gttctctcta tcgtcccgtc aggccccctc 60
aaagccgaga tcgcacagag acttgaagat gtctttgcag ggaagaacac cgatcttgag 120
gttctcatgg aatggctaaa gacaagacca atcctgtcac ctctgactaa ggggatttta 180
ggatttgtgt tcacgctcac cgtgcccagt gagcggggac tgcagcgtag acgctttgtc 240
caaaatgctc ttaatgggaa cggagatcca aataacatgg acaaagcagt taaactgtat 300
aggaagctta agagggagat aacattccat ggggccaaag aaatagcact cagttattct 360
gctggtgcac ttgccagttg tatgggcctc atatacaaca ggatgggggc tgtgaccact 420
gaagtggcat ttggcctggt atgcgcaacc tgtgaacaga ttgctgactc ccagcatcgg 480
tctcataggc aaatggtgac aacaaccaat ccactaatca gacatgagaa cagaatggtt 540
ctagccagca ctacagctaa ggctatggag caaatggctg gatcgagtga gcaagcagca 600
gaggccatgg atattgctag tcaggccagg caaatggtgc aggcgatgag aaccgttggg 660
actcatccta gctccagtgc tggtctaaaa gatgatcttc ttgaaaattt gcaggcctat 720
cagaaacgaa tgggggtgca gatgcaacga ttcaagtgat cctctcgtca ttgcagcaaa 780
tatcattgga atcttgcact tgatattgtg gattcttgat cgtctttttt tcaaatgcat 840
ttatcgtcgc tttaaatacg gtttgaaaag agggccttct acggaaggag tgccagagtc 900
tatgagggaa gaatatcgaa aggaacagca gaatgctgtg gatgttgacg atggtcattt 960
tgtcaacata gagctggagt aaaa 984
<210> 3
<211> 2202
<212> DNA
<213> 人工序列
<400> 3
ctgattcaaa atggaagatt ttgtgcgaca atgcttcaat ccgatgattg tcgagcttgc 60
ggaaaaggca atgaaagagt atggagagga cctgaaaatc gaaacaaaca aatttgcagc 120
aatatgcact cacttggaag tgtgcttcat gtattcagat tttcacttca tcgatgagca 180
aggcgagtca atagtcgtag aacttggcga tccaaatgca cttttgaagc acagatttga 240
aataatcgag ggaagagatc gcacaatagc ctggacagta ataaacagta tttgcaacac 300
tacaggggct gagaaaccaa agtttctacc agatttgtat gattacaaga agaatagatt 360
catcgaaatt ggagtaacaa ggagagaagt tcacatatac tatctggaaa aggccaataa 420
aattaaatct gagaagacac acatccacat tttctcattc actggggagg aaatggccac 480
aaaggccgac tacactctcg atgaagaaag cagggctagg atcaaaacca ggctattcac 540
cataagacaa gaaatggcta gcagaggcct ctgggattcc tttcgtcagt ccgagagagg 600
cgaagagaca attgaagaaa gatttgaaat cacaggaaca atgcgcaagc ttgccgacca 660
aagtctcccg ccaaacttct ccagccttga aaattttaga gcctatgtgg atggattcga 720
accgaacggc tacattgagg gcaagctttc tcaaatgtcc aaagaagtaa atgctagaat 780
tgaacctttt ttgaaatcaa caccacgacc acttagactt ccggatgggc ctccctgttc 840
tcagcggtcc aaattcctgc tgatggatgc cttaaaatta agcattgagg acccaagtca 900
tgagggagag gggataccgc tatatgatgc aatcaaatgc atgagaacat tctttggatg 960
gaaggaaccc aatgttgtta aaccacacga aaagggaata aatccaaatt atcttctgtc 1020
atggaagcaa gtactggcag aactgcagga cattgagaat gaggagaaaa ttccaaggac 1080
taaaaatatg aagaaaacga gtcagttaaa gtgggcactt ggtgagaaca tggcaccaga 1140
aaaggtagac tttgacgatt gtaaagatgt aggcgatttg aagcaatatg atagtgatga 1200
accagaattg aggtcgcttg caagttggat tcagaatgag ttcaacaagg catgtgaact 1260
gaccgattca agctggatag agctcgatga gattggagaa gatgcggctc caattgaaca 1320
cattgcaagc atgagaagga attatttcac agcagaggtg tctcattgca gagccacaga 1380
atacataatg aagggggtgt acatcaatac tgccttgctt aatgcatcct gtgcagcaat 1440
ggatgatttc caattgattc caatgataag caagtgtaga actaaggagg gaaggcgaaa 1500
gaccaatttg tacggtttca tcataaaagg aagatcccac ttaaggaatg acaccgatgt 1560
ggtaaacttt gtgagcatgg agttttccct cactgaccca agacttgaac cacacaaatg 1620
ggagaagtac tgtgttcttg aggtaggaga tatgcttcta agaagtgcca taggccatgt 1680
gtcaaggcct atgttcttgt atgtgaggac aaatggaacc tcaaaaatta aaatgaaatg 1740
ggggatggaa atgaggcgtt gcctccttca gtcacttcaa caaatcgaga gtatgattga 1800
agctgagtcc tctgtcaagg agaaagacat gaccaaagag ttctttgaaa acaaatcaga 1860
aacatggccc gttggagagt cccccaaagg agtggaggaa ggttccattg ggaaggtctg 1920
cagaacttta ttggcaaagt cggtattcaa cagcttgtat gcatctccac aactggaagg 1980
attttcagct gaatcaagaa aactgcttct tatcgttcag gctcttaggg acaacctgga 2040
acctgggacc tttgatcttg gggggctata tgaagcaatt gaggagtgcc tgattaatga 2100
tccctgggtt ttgcttaatg cttcttggtt caactccttc ctcacacatg cattgagata 2160
gttgtggcaa tgctactatt tgctatccat actgtccaaa aa 2202
<210> 4
<211> 2303
<212> DNA
<213> 人工序列
<400> 4
atttgaatgg atgtcaatcc gactttactt ttcttaaaag tgccagcaca aaatgctata 60
agcacaactt tcccttatac tggagaccct ccttacagcc atgggacagg aacaggatac 120
accatggata ctgtcaacag gacacatcag tactcagaaa ggggaagatg gacaacaaac 180
accgaaactg gagcaccgca actcaacccg attgatgggc cactgccaga agacaatgaa 240
ccaagtggtt atgcccaaac agattgtgta ttggaagcaa tggccttcct tgaggaatcc 300
catcctggta tctttgagac ctcgtgtctt gaaacgatgg aggttgttca gcaaacacga 360
gtggacaagc tgacacaagg ccgacagacc tatgactgga ctctaaatag gaaccagcct 420
gctgcaacag cattggccaa cacaatagaa gtgttcagat caaatggcct cacggccaat 480
gaatctggaa ggctcataga cttccttaag gatgtaatgg agtcaatgaa caaagaagaa 540
atggagatca caactcattt tcagagaaag agacgagtga gagacaatat gactaagaaa 600
atggtgacac agagaacaat aggtaaaagg aagcagagat tgaacaaaag gagttatcta 660
attagggcat taaccctgaa cacaatgacc aaagatgctg agagagggaa gctaaaacgg 720
agagcaattg caaccccagg gatgcaaata agggggtttg tatactttgt tgagacacta 780
gcaaggagta tatgtgagaa acttgaacaa tcaggattgc cagttggagg caatgagaag 840
aaagcaaagt tggcaaatgt tgtaaggaag atgatgacca attctcagga cactgaaatt 900
tctttcacca tcactggaga taacaccaaa tggaacgaaa atcagaaccc tcggatgttt 960
ttggccatga tcacatatat aaccagaaat cagcccgaat ggttcagaaa tgttctaagt 1020
attgctccaa taatgttctc aaacaaaatg gcgagactgg gaaaggggta catgtttgag 1080
agcaagagta tgaaacttag aactcaaata cctgcagaaa tgctagcaag catcgatttg 1140
aaatacttca atgattcaac tagaaagaag attgaaaaaa tccggccgct cttaatagat 1200
gggactgcat cattgagccc tggaatgatg atgggcatgt tcaatatgtt aagtactgta 1260
ttaggcgtct ccatcctgaa tcttggacaa aagagacaca ccaagactac ttactggtgg 1320
gatggtcttc aatcttctga tgattttgct ctgattgtga atgcacccaa tcatgaaggg 1380
attcaagccg gagtcaacag gttttatcga acctgtaagc tacttggaat taatatgagc 1440
aagaaaaagt cttacataaa cagaacaggt acatttgaat tcacaagttt tttctatcgt 1500
tatgggtttg ttgccaattt cagcatggag cttcccagct ttggggtgtc tgggatcaac 1560
gagtctgcgg acatgagtat tggagttact gtcatcaaaa acaatatgat aaacaatgat 1620
cttggtccag caaccgctca aatggccctt cagctgttca tcaaagatta caggtacacg 1680
taccggtgcc atagaggtga cacacaaata caaacccgaa gatcatttga aataaagaaa 1740
ctgtgggagc aaacccattc caaagctgga ctgctggtct ccgacggagg cccaaattta 1800
tacaacatta gaaatctcca cattcctgaa gtctgcttga aatgggaatt aatggatgag 1860
gattaccagg ggcgtttatg caacccactg aacccatttg tcaaccataa agacattgaa 1920
tcagtgaaca atgcagtgat aatgccagca catggtccag ccaaaaacat ggagtatgat 1980
gctgttgcaa caacacactc ctggatcccc aaaagaaatc gatccatctt gaatacaagc 2040
caaagaggaa tacttgaaga tgaacaaatg taccaaaagt gctgcaactt atttgaaaaa 2100
ttcttcccca gcagttcata cagaagacca gtcgggatat ccagtatggt ggaggctatg 2160
gtttccagag cccgaattga tgcacgaatt gatttcgaat ctggaaggat aaagaaagag 2220
gagttcactg agatcatgaa gatctgttcc accattgaag agctcagacg gcaaaaatag 2280
tgaatttagc ttgtccttca tga 2303
<210> 5
<211> 2290
<212> DNA
<213> 人工序列
<400> 5
atggaaagaa taaaagaact aaggaatcta atgtcgcagt ctcgcactcg cgagatactc 60
acaaaaacca ccgtggacca tatggccata atcaagaagt acacatcagg aagacaggag 120
aagaacccag cacttaggat gaaatggatg atggcaatga aatatccaat tacagcagac 180
aagaggataa cggaaatgat tcctgagaga aatgagcagg gacaaacttt atggagtaaa 240
atgaatgacg ccggatcaga ccgagtgatg gtatcacctc tggctgtgac atggtggaat 300
aggaatggac cagtgacaag tacagttcat tatccaaaaa tctacaaaac ttattttgaa 360
aaagtcgaaa ggttaaaaca tggaaccttt ggccctgtcc attttagaaa ccaagtcaaa 420
atacgtcgaa gagttgacat aaatcctggt catgcagatc tcagtgccaa agaggcacag 480
gatgtaatca tggaagttgt tttccctaac gaagtgggag ccaggatact aacatcggaa 540
tcgcaactaa cgacaaccaa agagaagaaa gaagaactcc agggttgcaa aatttctcct 600
ctgatggtgg catacatgtt ggagagagaa ctggtccgca aaacgagatt cctcccagtg 660
gctggtggaa caagcagtgt gtacattgaa gtgttgcatt tgacccaagg aacatgctgg 720
gaacagatgt acactccagg aggggaggcg aggaatgatg atgttgatca aagcttaatt 780
attgctgcta gaaacatagt aagaagagcc acagtatcag cagatccact agcatcttta 840
ttggagatgt gccacagcac gcagattggt ggagtaagga tggtaaacat ccttaggcag 900
aacccaacag aagagcaagc cgtggatatt tgcaaggctg caatgggact gagaattagc 960
tcatccttca gttttggtgg attcacattt aagagaacaa gcggatcatc agtcaagaga 1020
gaggaagagg tgcttacggg caatcttcag acattgaaga taagagtgca tgagggatat 1080
gaagagttca caatggttgg gagaagagca acagctatac tcagaaaagc aaccaggaga 1140
ttgattcagc tgatagtgag tgggagagac gaacagtcga ttgccgaagc aataattgtg 1200
gccatggtat tttcacaaga ggattgtatg ataaaagcag ttagaggtga cctgaatttc 1260
gtcaataggg cgaatcagcg attgaatccc atgcaccaac ttttgagaca ttttcagaag 1320
gatgcaaagg tgctctttca aaattgggga attgaatcca tcgacaatgt gatgggaatg 1380
atcgggatat tgcccgacat gactccaagc accgagatgt caatgagagg agtgagaatc 1440
agcaaaatgg gggtagatga gtattccagc gcggagaaga tagtggtgag cattgaccgt 1500
tttttgagag ttagggacca acgtgggaat gtactactgt ctcccgagga ggtcagtgaa 1560
acacagggaa cagagaaact gacaataact tactcatcgt caatgatgtg ggagattaat 1620
ggtcctgaat cagtgttggt caatacctat cagtggatca tcagaaactg ggaaactgtt 1680
aaaattcagt ggtcccagaa tcctacaatg ctgtacaata aaatggaatt tgagccattt 1740
cagtctttag ttccaaaggc cgttagaggc caatacagtg ggtttgtgag aactctgttc 1800
caacaaatga gggatgtgct tgggacattt gataccgctc agataataaa acttcttccc 1860
ttcgcagccg ctccaccaaa gcaaagtgga atgcagttct cctcattgac tataaatgtg 1920
aggggatcag gaatgagaat acttgtaagg ggcaattctc cagtattcaa ctacaacaag 1980
accactaaaa gactcacagt tctcggaaag gatgctggcc ctttaactga agacccagat 2040
gaaggcacag ctggagttga gtccgcagtt ctgagaggat tcctcattct gggcaaagaa 2100
gacaggagat atggaccagc attaagcata aatgaactga gcaaccttgc gaaaggagag 2160
aaggctaatg tgctaattgg gcaaggagac gtggtgttgg taatgaaacg gaaacggaac 2220
tctagcatac ttactgacag ccagacagcg accaaaagaa ttcggatggc catcaattag 2280
tgtcgaatag 2290
<210> 6
<211> 1725
<212> DNA
<213> 人工序列
<400> 6
ccaaaatgaa ggcaaaacta ctggtcctgt tatatgcatt tgtagctaca gatgcagaca 60
caatatgtat aggctaccat gcgaacaact caaccgacac tgttgacaca atattcgaga 120
agaatgtggc agtgacacat tctgttaacc tgctcgaaga cagacacaac gggaaactat 180
gtaaattaaa aggaatagcc ccactacaat tggggaaatg taacatcatc ggatggctct 240
tgggaaatcc agaatgcgac tcactgcttc cagcgagatc atggtcctac attgtagaaa 300
caccaaactc tgagaatgga gcatgttatc caggagattt catcgactat gaggaactga 360
gggagcaatt gagctcagta tcatcattag aaagattcga aatatttccc aaggaaagtt 420
catggcccaa ccacacattc aacggagtaa cagcatcatg ctcccatagg ggaaaaagca 480
gtttttacag aaatttgcta tggctgacga agaaggggga ttcataccca aagctgacca 540
attcctatgt gaacaataaa gggaaagaag tccttgtact atggggtgtt catcacccgt 600
ctagcagtga tgagcaacag agtctctata gtaatggaaa tgcttatgtc tctgtagcgt 660
cttcaaatta taacaggaga ttcaccccgg aaatagctgc aaggcccaaa gtaaaagatc 720
aacatgggag gatgaactat tactggacct tgctagaacc cggagacaca ataatatttg 780
aggcaactgg taatctaata gcaccatggt atgctttcgc actgagtaga gggtttgagt 840
ccggcatcat cacctcaaac gcgtcaatgc atgagtgtaa cacgaagtgt caaacacccc 900
agggatctat aaacagcaat ctccctttcc agaatataca cccagtcaca ataggagagt 960
gcccaaaata tgtcaggagt accaaattga ggatggttac aggactaaga aacatcccat 1020
ccattcaata cagaggtcta tttggagcca ttgctggttt tattgagggg ggatggactg 1080
gaatgataga tggatggtat ggttatcatc atcagaatga acagggatca ggctatgcag 1140
cggatcaaaa aagcacacag aatgccatta acgggattac aaacaaggtg aactctatta 1200
tcgagaaaat gaacactcaa ttcacagctg tgggtaaaga attcaacaac ttagaaaaaa 1260
ggatggaaaa tttaaataaa aaagttgatg atgggtttct ggacatttgg acatataatg 1320
cagaattgtt agttctactg gaaaatggaa gaactttgga tttccatgac ttaaatgtga 1380
agaatctgta cgagaaagta aaaagccaat taaagaataa tgccaaagaa atcggaaatg 1440
ggtgttttga gttctaccac aagtgtgaca atgaatgcat ggaaagtgta agaaatggga 1500
cttatgatta tccaaaatat tcagaagaat caaagttgaa cagggaaaag atagatggag 1560
tgaaattgga atcaatgggg gtgtatcaga ttctggcgat ctactcaact gtcgccagtt 1620
cactggtgct tttggtctcc ctgggggcaa tcagtttctg gatgtgttct aatgggtctt 1680
tgcagtgcag aatatgcatc tgagattagg atttcagaaa tataa 1725
<210> 7
<211> 1526
<212> DNA
<213> 人工序列
<400> 7
tcactcacag agtgacatcg aaatcatggc gaccaaaggc accaaacgat cttacgaaca 60
gatggagact gatggagaac gccagaatgc cactgaaatc agagcatctg tcggaaaaat 120
gattgatgga attggacgat tctacatcca aatgtgcacc gaacttaaac tcagtgatta 180
tgagggacgg ctgattcaga acagcttaac aatagagaga atggtgctct ctgcttttga 240
cgagaggagg aataaatatc tagaagaaca tcccagtgcg gggaaagatc ctaagaaaac 300
tggaggacct atatacagga gagtagatgg aaagtggagg agagaactca tcctttatga 360
caaagaagaa ataagacgaa tctggcgcca agctaataat ggtgacgatg caacggctgg 420
tctgactcac atgatgatct ggcactccaa tttgaatgat gcaacttacc agaggacaag 480
agctcttgtt cgcacaggaa tggatcccag gatgtgctca ctgatgcagg gttcaaccct 540
ccctaggagg tctggggccg caggtgctgc agtcaaagga gttggaacaa tggtgatgga 600
attgatcaga atgatcaaac gtgggatcaa tgatcggaac ttctggaggg gtgagaatgg 660
acggagaaca aggattgctt atgaaagaat gtgcaacatt ctcaaaggga aatttcaaac 720
agctgcacaa agaacaatgg tggatcaagt gagagagagc cggaatccag gaaatgctga 780
gttcgaagat ctcatctttt tagcacggtc tgcactcata ttgagagggt cagttgctca 840
caagtcctgc ctgcctgcct gtgtgtatgg atctgccgta gccagtggat acgactttga 900
aagagaggga tactctctag tcggaataga ccctttcaga ctgcttcaaa acagccaagt 960
atacagccta atcagaccaa atgagaatcc agcacacaag agtcaactgg tgtggatggc 1020
atgccattct gctgcatttg aagatctaag agtatcaagc ttcatcagag ggacgaaagt 1080
ggtcccaaga gggaagcttt ccactagagg agttcaaatt gcttccaatg aaaacatgga 1140
gactatggaa tcaagtaccc ttgaactgag aagcagatac tgggccataa ggaccagaag 1200
tggagggaac accaatcaac agagggcttc ctcgggccaa atcagcatac aacctacgtt 1260
ctcagtacag agaaatctcc cttttgacag accaaccatt atggcagcat tcactgggaa 1320
tacagagggg agaacatctg acatgagaac cgaaatcata aggctgatgg aaagtgcaag 1380
accagaagat gtgtctttcc aggggcgggg agtcttcgag ctctcggacg aaaaggcaac 1440
gagcccgatc gtgccctcct ttgacatgag taatgaagga tcttatttct tcggagacaa 1500
tgcagaggag tacgacaatt aaagaa 1526
<210> 8
<211> 1368
<212> DNA
<213> 人工序列
<400> 8
atgaatccaa accagaaaat aataaccatt gggtcaatct gtatggtagt cggaataatt 60
agcctaatat tgcaaatagg aaatataatc tcaatatgga ttagccattc aattcaaacc 120
ggaaatcaaa accatactgg aatatgcaac caaggcagca ttacctataa agttgttgct 180
gggcaggact caacttcagt gatattaacc ggcaattcat ctctttgtcc catccgtggg 240
tgggctatac acagcaaaga caatggcata agaattggtt ccaaaggaga cgtttttgtc 300
ataagagagc cttttatttc atgttctcac ttggaatgca ggaccttttt tctgactcaa 360
ggcgccttac tgaatgacaa gcattcaagg gggaccttta aggacagaag cccttatagg 420
gccttaatga gctgccctgt cggtgaagct ccgtccccgt acaattcaag gtttgaatcg 480
gttgcttggt cagcaagtgc atgtcatgat ggaatgggct ggctaacaat cggaatttct 540
ggtccagatg atggagcagt ggctgtatta aaatacaacg gcataataac tgaaaccata 600
aaaagttgga ggaagaatat attgagaaca caagagtctg aatgtacctg tgtaaatggt 660
tcatgtttta ccataatgac cgatggccca agtgatgggc tggcctcgta caaaattttc 720
aagatcgaga aggggaaggt tactaaatca atagagttga atgcacctaa ttctcactac 780
gaggaatgtt cctgttaccc tgataccggc aaagtgatgt gtgtgtgcag agacaattgg 840
cacggttcga accgaccatg ggtgtccttc gaccaaaacc tagattataa aataggatac 900
atctgcagtg gggttttcgg tgacaacccg cgtcccaaag atggaacagg cagctgtggc 960
ccagtgtctg ctgatggagc aaacggagta aagggatttt catataagta tggtaatggt 1020
gtttggatag gaaggactaa aagtgacagt tccagacatg ggtttgagat gatttgggat 1080
cctaatggat ggacagagac tgatagtagg ttctctatga gacaagatgt tgtggcaatg 1140
actgatcggt cagggtacag cggaagtttc gttcaacatc ctgagctaac agggctagac 1200
tgtatgaggc cttgcttctg ggttgaatta atcagggggc tacctgagga gaacgcaatc 1260
tggactagtg ggagcatcat ttctttttgt ggtgtgaata gtgatactgt agattggtct 1320
tggccagacg gtgctgagtt gccgttcacc attgacaagt agtttgtt 1368
<210> 9
<211> 845
<212> DNA
<213> 人工序列
<400> 9
aatggatcca aacactgtgt caagctttca ggtagattgc tttctttggc atgtccgcaa 60
aagagttgca gaccaagaac taggtgatgc cccattcctt gatcggcttc gccgagatca 120
gaagtcccta agaggaagag gcagcactct cggtctggac atcgaaacag ccacccgtgc 180
tggaaagcaa atagtggagc ggattctgaa ggaagaatct gatgaggcac tcaaaatgac 240
catggcctct gtacctgcat cgcgctacct aactgacatg actcttgagg aaatgtcaag 300
gcactggttc atgctcatgc ccaagcagaa agtggcaggc cctctttgta tcagaatgga 360
ccaggcgatc atggataaga acatcatact gaaagcgaac ttcagtgtga tttttgaccg 420
gctggagact ctaatattac taagggcctt caccgaagag gggacaattg ttggcgaaat 480
ttcaccactg ccctctcttc caggacatac tgatgaggat gtcaaaaatg cagttggggt 540
cctcatcgga ggacttgaat ggaataataa cacagttcga gtctctgaaa ctctacagag 600
attcgcttgg agaagcagta atgagaatgg gagacctcca ctcactccaa aacagaaacg 660
gaaaatggcg ggaacaatta ggtcagaagt ttgaagaaat aagatggttg attgaagaag 720
tgagacacag actgaagata acagagaata gttttgagca aataacattt atgcaagcct 780
tacaactatt gcttgaagtg gagcaagaga taagaacttt ctcgtttcag cttatttaat 840
aataa 845
<210> 10
<211> 1526
<212> DNA
<213> 人工序列
<400> 10
tcactcacag agtgacatcg aaatcatggc gaccaaaggc accaaacgat cttacgaaca 60
gatggagact gatggagaac gccagaatgc cactgaaatc agagcatctg tcggaaaaat 120
gattgatgga attggacgat tctacatcca aatgtgcacc gaacttaaac tcagtgatta 180
tgagggacgg ctgattcaga acagcttaac aatagagaga atggtgctct ctgcttttga 240
cgagaggagg aataaatatc tagaagaaca tcccagtgcg gggaaagatc ctaagaaaac 300
tggaggacct atatacagga gagtagatgg aaagtggagg agagaactca tcctttatga 360
caaagaagaa ataagacgaa tctggcgcca agctaataat ggtgacgatg caacggctgg 420
tctgactcac atgatgatct ggcactccaa tttgaatgat gcaacttacc agaggacaag 480
agctcttgtt cgcacaggaa tggatcccag gatgtgctca ctgatgcagg gttcaaccct 540
ccctaggagg tctggggccg caggtgctgc agtcaaagga gttggaacaa tggtgatgga 600
attgatcaga atgatcaaac gtgggatcaa tgatcggaac ttctggaggg gtgagaatgg 660
acggagaaca aggattgctt atgaaagaat gtgcaacatt ctcaaaggga aatttcaaac 720
agctgcacaa agaacaatgg tggatcaagt gagagagagc cggaatccag gaaatgctga 780
gttcgaagat ctcatctttt tagcacggtc tgcactcata ttgagagggt cagttgctca 840
caagtcctgc ctgcctgcct gtgtgtatgg atctgccgta gccagtggat acgactttga 900
aagagaggga tactctctag tcggaataga ccctttcaga ctgcttcaaa acagccaagt 960
atacagccta atcagaccaa atgagaatcc agcacacaag agtcaactgg tgtggatggc 1020
atgccattct gctgcatttg aagatctaag agtatcaagc ttcatcagag ggacgaaagt 1080
ggtcccaaga gggaagcttt ccactagagg agttcaaatt gcttccaatg aaaacatgga 1140
gactatggaa tcaagtaccc ttgaactgag aagcagattc tgggccataa ggaccagaag 1200
tggagggaac accaatcaac agagggcttc ctcgggccaa atcagcatac aacctacgtt 1260
ctcagtacag agaaatctcc cttttgacag accaaccatt atggcagcat tcactgggaa 1320
tacagagggg agaacatctg acatgagaac cgaaatcata aggctgatgg aaagtgcaag 1380
accagaagat gtgtctttcc aggggcgggg agtcttcgag ctctcggacg aaaaggcaac 1440
gagcccgatc gtgccctcct ttgacatgag taatgaagga tcttatttct tcggagacaa 1500
tgcagaggag tacgacaatt aaagaa 1526
Claims (8)
1.一种重组病毒,是将A型流感病毒基因组中编码NP蛋白的第385位酪氨酸残基的密码子突变为苯丙氨酸残基的密码子得到的重组病毒。
2.如权利要求1所述的重组病毒,其特征在于:所述NP蛋白如序列表的序列1所示。
3.一种蛋白质,是将NP蛋白的第385位酪氨酸残基突变为苯丙氨酸残基得到的蛋白质。
4.编码权利要求3所述蛋白质的基因。
5.含有权利要求4所述基因的重组质粒。
6.一种重组病毒,其制备方法包括如下步骤:
将质粒pHH21-PA、质粒pHH21-PB1、质粒pHH21-PB2、质粒pHH21-HA、质粒pHH21-NA、质粒pHH21-M、质粒pHH21-NS、质粒pcDNA3.0-PA、质粒pcDNA3.0-PB1、质粒pcDNA3.0-PB2、重组质粒pHH21-NP-Y385F和重组质粒pcDNA3.0-NP-Y385F共转染离体哺乳动物细胞后进行培养得到的重组病毒;
所述质粒pHH21-PA为在载体pHH21的多克隆位点插入序列表的序列3所示的双链DNA分子得到的质粒;所述质粒pHH21-PB1为在载体pHH21的多克隆位点插入序列表的序列4所示的双链DNA分子得到的质粒;所述质粒pHH21-PB2为在载体pHH21的多克隆位点插入序列表的序列5所示的双链DNA分子得到的质粒;所述质粒pHH21-HA为在载体pHH21的多克隆位点插入序列表的序列6所示的双链DNA分子得到的质粒;所述质粒pHH21-NA为在载体pHH21的多克隆位点插入序列表的序列8所示的双链DNA分子得到的质粒;所述质粒pHH21-M为在载体pHH21的多克隆位点插入序列表的序列2所示的双链DNA分子得到的质粒;所述质粒pHH21-NS为在载体pHH21的多克隆位点插入序列表的序列9所示的双链DNA分子得到的质粒;所述质粒pcDNA3.0-PA为在载体pcDNA3.0的多克隆位点插入序列表的序列3所示的双链DNA分子得到的质粒;所述质粒pcDNA3.0-PB1为在载体pcDNA3.0的多克隆位点插入序列表的序列4所示的双链DNA分子得到的质粒;所述质粒pcDNA3.0-PB2为在载体pcDNA3.0的多克隆位点插入序列表的序列5所示的双链DNA分子得到的质粒;所述重组质粒pHH21-NP-Y385F为在载体pHH21的多克隆位点插入权利要求4所述基因得到的质粒;所述重组质粒pcDNA3.0-NP-Y385F为在载体pcDNA3.0的多克隆位点插入权利要求4所述基因得到的质粒。
7.权利要求1或2或6所述重组病毒在制备A型流感病毒疫苗中的应用。
8.一种A型流感病毒疫苗,其活性成分为权利要求1或2或6所述重组病毒。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710028543.8A CN106834238B (zh) | 2017-01-16 | 2017-01-16 | A型流感病毒温度敏感性的关键磷酸化位点及其应用 |
PCT/CN2017/072063 WO2018129767A1 (zh) | 2017-01-16 | 2017-01-22 | A型流感病毒温度敏感性的关键磷酸化位点及其应用 |
US16/085,469 US10538745B2 (en) | 2017-01-16 | 2017-01-22 | Key phosphorylation site of temperature sensitivity of influenza A virus and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710028543.8A CN106834238B (zh) | 2017-01-16 | 2017-01-16 | A型流感病毒温度敏感性的关键磷酸化位点及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106834238A CN106834238A (zh) | 2017-06-13 |
CN106834238B true CN106834238B (zh) | 2020-04-14 |
Family
ID=59124748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710028543.8A Active CN106834238B (zh) | 2017-01-16 | 2017-01-16 | A型流感病毒温度敏感性的关键磷酸化位点及其应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US10538745B2 (zh) |
CN (1) | CN106834238B (zh) |
WO (1) | WO2018129767A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109464670B (zh) * | 2017-09-08 | 2022-08-02 | 中国科学院微生物研究所 | 调控a型和b型流感病毒核蛋白出核的关键氨基酸位点及其作为抗流感病毒药物靶点的用途 |
CN107964035B (zh) * | 2017-12-06 | 2020-07-24 | 中国科学院微生物研究所 | 一种用于流感病毒的有限复制型黏膜免疫疫苗 |
CN111363017B (zh) * | 2018-12-25 | 2022-03-15 | 中国科学院微生物研究所 | A型流感病毒核蛋白s69位突变序列及其突变体与应用 |
CN112708601B (zh) * | 2019-10-24 | 2023-08-18 | 上海市农业科学院 | H1n1猪流感病毒ns1蛋白磷酸化位点丢失病毒的制备方法 |
CN117946982A (zh) * | 2022-12-30 | 2024-04-30 | 中国科学院微生物研究所 | H1n1流感病毒冷适应疫苗骨架毒株cv1-pr8及其构建方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101186637A (zh) * | 2007-11-14 | 2008-05-28 | 中国科学院微生物研究所 | 抑制流感病毒感染的方法及其药物 |
CN104592367A (zh) * | 2014-12-24 | 2015-05-06 | 中国科学院微生物研究所 | 流感病毒np蛋白突变体及其编码基因与应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016172588A1 (en) | 2015-04-24 | 2016-10-27 | Andrew Cox | Attenuated influenza vaccines and uses thereof |
-
2017
- 2017-01-16 CN CN201710028543.8A patent/CN106834238B/zh active Active
- 2017-01-22 WO PCT/CN2017/072063 patent/WO2018129767A1/zh active Application Filing
- 2017-01-22 US US16/085,469 patent/US10538745B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101186637A (zh) * | 2007-11-14 | 2008-05-28 | 中国科学院微生物研究所 | 抑制流感病毒感染的方法及其药物 |
CN104592367A (zh) * | 2014-12-24 | 2015-05-06 | 中国科学院微生物研究所 | 流感病毒np蛋白突变体及其编码基因与应用 |
Non-Patent Citations (4)
Title |
---|
Mapping the Phosphoproteome of Influenza A and B Viruses by Mass Spectrometry.;Hutchinson et al.;《PLOS Pathogens》;20121130;第8卷(第11期);e1002993 * |
Mutational Analysis of Conserved Amino Acids in the Influenza A Virus Nucleoprotein.;Li et al.;《JOURNAL OF VIROLOGY》;20090218;第83卷(第9期);4153-4162 * |
PR8流感病毒突变株的制备及其在鸡胚上生长特性的研究;王朝霞等;《中国兽医科学》;20100820;第40卷(第8期);788-792 * |
Specific Nucleoprotein Residues Affect Influenza Virus Morphology.;Bialas et al.;《Journal of Virology》;20141231;第88卷(第4期);2227-2234 * |
Also Published As
Publication number | Publication date |
---|---|
US20190085302A1 (en) | 2019-03-21 |
US10538745B2 (en) | 2020-01-21 |
WO2018129767A1 (zh) | 2018-07-19 |
CN106834238A (zh) | 2017-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106834238B (zh) | A型流感病毒温度敏感性的关键磷酸化位点及其应用 | |
CN113185613B (zh) | 新型冠状病毒s蛋白及其亚单位疫苗 | |
JP2534246B2 (ja) | ニユ−カツスル病ウイルス遺伝子クロ−ン | |
CN113943373B (zh) | 一种β冠状病毒多聚体抗原、其制备方法和应用 | |
Tahara et al. | Multiple Amino Acid Substitutions in Hemagglutinin Are Necessary for Wild-Type MeaslesVirus To Acquire the Ability To Use Receptor CD46 Efficiently | |
CN110951699B (zh) | 表达犬瘟热病毒结构蛋白的重组狂犬病病毒及其应用 | |
JP7189224B2 (ja) | Anp32蛋白質の宿主体内でのインフルエンザウィルスポリメラーゼ活性の維持への使用 | |
Bousse et al. | Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment | |
Huang et al. | African swine fever virus HLJ/18 CD2v suppresses type I IFN production and IFN-stimulated genes expression through negatively regulating cGMP-AMP synthase–STING and IFN signaling pathways | |
Liu et al. | African swine fever virus pE301R negatively regulates cGAS-STING signaling pathway by inhibiting the nuclear translocation of IRF3 | |
Yang et al. | Regulation of viral RNA synthesis by the V protein of parainfluenza virus 5 | |
CN116622641A (zh) | Ace2和tmprss2双过表达细胞系及其制备方法和应用 | |
Fukuhara et al. | Mutational analysis of the Sendai virus V protein: importance of the conserved residues for Zn binding, virus pathogenesis, and efficient RNA editing | |
WO2023196759A2 (en) | Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant | |
CN114989266B (zh) | 一种非洲猪瘟病毒pA104R蛋白免疫抑制相关氨基酸位点及其应用 | |
CN107964035B (zh) | 一种用于流感病毒的有限复制型黏膜免疫疫苗 | |
Schaap-Nutt et al. | Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates | |
US20080069830A1 (en) | Dna Sequences, Peptides, Antibodies and Vaccines for Prevention and Treatment of Sars | |
CN112442492B (zh) | 流感病毒pb1蛋白突变体及其编码基因与应用 | |
KR101788234B1 (ko) | 발육란 고증식성 무병원성 재조합 인플루엔자 바이러스 및 이의 용도 | |
CN116284265B (zh) | 一种不受Hrd1泛素化降解的突变CDV H蛋白、突变CDV病毒及应用 | |
CN111363017A (zh) | A型流感病毒核蛋白s69位突变序列及其突变体与应用 | |
CN116621949B (zh) | 一种增加狂犬病毒g蛋白分泌表达的方法及应用 | |
Kimura et al. | Sarbecovirus ORF6 proteins hamper the induction of interferon signaling by blocking mRNA nuclear export | |
KR101788236B1 (ko) | 무병원성 및 고면역원성 인플루엔자 바이러스 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |